AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

by Barry101 | Jan 10, 2024 | Press Release

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla., Jan. 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM)...

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

by Barry101 | Jan 5, 2024 | Press Release

OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have elected all four of the Company’s directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William...

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

by Barry101 | Dec 29, 2023 | Press Release

Court Finds Activist Group “Flouted” AIM’s Bylaws by Failing to Provide Required Information AIM Will Reconvene Annual Meeting Today and then Adjourn Until January 5th Any Proxies Submitted by Activist Group Will Be Disregarded AIM Urges Shareholders...

AIM ImmunoTech Provides Update Regarding Annual Meeting

by Barry101 | Nov 28, 2023 | Press Release

AIM Will Convene Annual Meeting on December 1st and then Adjourn Until December 29th to Give Delaware Court Additional Time to Deliver Ruling in Activist Group Litigation OCALA, Fla. – AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

by Barry101 | Nov 27, 2023 | Press Release

Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the...